What is the recommended treatment for maternal toxoplasmosis to decrease congenital infection risk?

The recommended treatment for maternal toxoplasmosis to decrease the risk of congenital infection is Spiramycin. Spiramycin is an antibiotic that is effective in treating toxoplasmosis during pregnancy. It is crucial because it can help reduce the transmission of the parasite from the mother to the fetus, ultimately decreasing the likelihood of congenital toxoplasmosis, which can lead to serious developmental issues in the newborn.

Spiramycin works specifically to reduce the risk of transmission if given early in the pregnancy. Pregnant women who test positive for toxoplasmosis are often treated with Spiramycin, especially if they are asymptomatic, as it can effectively lower the chance of the fetus becoming infected without posing additional risks that other treatments might carry.

While Pyrimethamine and Sulfadiazine are effective treatments for toxoplasmosis in general, they are not preferred during pregnancy due to associated risks, including potential adverse effects on fetal development. Pyrimethamine in particular is associated with bone marrow suppression, and its safety in pregnancy has not been established. Therefore, it is generally not recommended as a first-line treatment for maternal toxoplasmosis in pregnant women.

The choice of Spiramycin aims to provide a safer option for managing the infection while minimizing risks to the